Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06893757

Prospective Cohort of People Starting Treatment for Tuberculosis Disease in France (FrenchTB)

The French Tuberculosis Cohort is a prospective, national, multicenter, low-intervention study including subjects aged 18 years and older with tuberculosis disease for which inpatient treatment is initiated. The goal of this observational study is to follow-up and anti-tuberculosis treatment will be provided according to current French recommendations. Participants will provide sociodemographic, clinical, biological, radiological and bacteriological data at various protocol visits at 2 days, 1 and 2 weeks, 2 months, at the end of treatment, 12 and 24 months. Consenting participants will have samples collected at scheduled visits for the establishment of a biobank. This will include blood, urine, breath and hair samples. The positive mycobacterial strains will constitute a specimen bank.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

AP-HP Hôpital Saint Louis - Service des Maladies Infectieuses et Tropicales, Paris, France

Loading trial locations.

About this study

Main objectif:

To describe the sociodemographic, clinical, radiologic, and bacteriologic characteristics, as well as comorbidities and their impact on treatment outcomes and relapse rate up to 24 months after the start of anti-tuberculosis treatment in people with tuberculosis disease diagnosed in France.

Secondary objectives:

  • Evaluate the effects of immunosuppression (HIV infection, organ transplantation, immunosuppressive treatments) on tuberculosis symptomatology, complications (including immune reconstitution inflammatory syndromes (IRIS), and drug interactions), treatment response and survival.
  • Describe the characteristics of severe (meningeal, pericardial, miliary, etc.) or complicated forms of tuberculosis, including resistant tuberculosis, their management (treatment of resistant TB, use of anti-TNF, corticoids), their impact on treatment outcomes, relapse rates up to 24 months, sequelae and survival.
  • Describe representations of the disease and its care, its impact on quality of life, and the effect of social determinants, situations of precariousness, health literacy, belonging to key populations (incarcerated, migrant and/or homeless people) as well as mental health disorders and addictions on compliance, experience of the disease, follow-up, and treatment outcomes.
  • Describe the effect of new short-course tuberculosis treatments on adherence, disease experience, follow-up and treatment outcomes.
  • Describe post-tuberculosis pulmonary sequelae, study their association with immunosuppression, pharmacological dosages, other comorbidities, tobacco and alcohol consumption, and measure physiological, structural and functional disorders, their impact on quality of life and survival.
  • Study the potential diagnostic and prognostic value of new biomarkers in people with tuberculosis and the effect of exposure to anti-tuberculosis treatment on response to tuberculosis therapy.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged ≥18 years.
  • Diagnosis of tuberculosis by microbiological or clinical means, including on the basis of a pathological examination for extrapulmonary tuberculosis leading to a Compulsory Declaration (CD) and treated for less than 8 days.
  • Have signed a voluntary, informed and written consent (at the latest on the day of inclusion and before any examination carried out as part of the research), or alternatively, consent from relatives in cases of tuberculous meningitis or other serious forms of tuberculosis with impaired consciousness or confusion, until the person is able to give their consent.

Exclusion criteria

  • Presence of significant cognitive impairment that, in the opinion of the site investigator or designated person, may affect the ability to give reliable informed consent (except in the specific case of meningeal tuberculosis).

Treatment and study plan

Primary outcomes

  1. Proportion of participants with successful anti-tuberculosis treatment outcome, defined as definite or probable cure, by Month 12

    Time frame: through treatment completion; Month 12

    Definite cure (microbiological): negative cultures (or direct examination) of respiratory specimens on two occasions during follow-up, in the last month of treatment and on an intermediate specimen, in a participant who has completed treatment and has never met the definition of treatment failure.

  2. Success of the anti-tuberculosis treatment

    Time frame: through treatment completion; Month 12

    Probable cure: clinical and radiological improvement of tuberculosis-related symptoms in a participant who has completed treatment and never met the definition of treatment failure.

Secondary outcomes

  1. Early microbiological response

    Time frame: Month 2

    Assessed by the conversion (negativation) of cultures specimens on two occasions during follow-up, in the last month of treatment and on an intermediate specimen, in a participant who has completed treatment and has never met the definition of treatment failure.

  2. Positive culture

    Time frame: Month 5

    Number of Positive culture after 5 months of treatment

  3. Tuberculosis-related death

    Time frame: Month 5

    Number of deaths directly related to tuberculosis in the year following diagnosis

  4. Premature treatment interruption without resumption

    Time frame: Month 5

    Number of interrupted treatments before the end of the planned duration and not resumed (for a reason other than a rejected tuberculosis diagnosis

  5. Ongoing treatment at Month 12 due to interruption, resistance, adverse events, or initial failure

    Time frame: Month 12

    Number of treatment ongoing at 12 months because interrupted for more than two months or modified for resistance, side effects/intolerance, initial failure

  6. Transfer or loss to follow-up

    Time frame: Month 5

    Number of transfers or loss of follow-up

  7. All-cause mortality

    Time frame: Until Month 24

    Occurrence and causes of death after tuberculosis diagnosis after inclusion and causes

  8. Tuberculosis relapse

    Time frame: Between end of treatment and Month 24

    Recurrence of positive culture of respiratory samples after the end of treatment and after cultures become negative during treatment

  9. Clinical and radiological post-tuberculosis respiratory sequelae and not related to another pulmonary pathology

    Time frame: treatment completion until Month 24

    Rate of persistent respiratory symptoms such as coughing, dyspnoea, chest pain and/or wheezing

  10. Clinical and radiological post-tuberculosis respiratory sequelae and not related to another pulmonary pathology and/or hypoxaemia

    Time frame: treatment completion until Month 24

    Oxygen saturation 88% or lower and PaO2 lower 60 mmHg in ambient air at a distance from an acute episode

  11. Clinical and radiological post-tuberculosis respiratory sequelae and not related to another Pulmonary pathology

    Time frame: Baseline, completion or failure treatment (up to 12 months)

    and/or impaired lung function as measured by spirometry (FEV1 or FVC <80% of the theoretical value or FEV1/FVC ratio <0.70) iv) and/or radiological sequelae defined as the persistence of pulmonary parenchymal abnormalities (nodules, cavities, reticulations, etc.). The anomalies should not be linked to an obvious cause unrelated to tuberculosis (COPD).

  12. Functional impact and repercussions of respiratory sequelae

    Time frame: Baseline, Month 12, completion or failure treatment

    The 3 components of the St Georges's Respiratory Questionnaire (SGRQ): symptoms (frequency and severity), activity (effects on and adjustment of everyday activities), and psychosocial impact. The total score has a maximum of 100 points, with values ranging from 0 to 100.

  13. Functional impact and repercussions of respiratory sequelae

    Time frame: Completion treatment, Month 24

    Functional evaluation measured by the 6-minute walk test

  14. Functional impact and repercussions of respiratory sequelae

    Time frame: Completion treatment (up to 12 months), Month 24

    Spirometry - FEV1/FVC ratio of greater than 0.70 and both FEV1 and FVC above 80% of the predicted value

  15. Functional impact and repercussions of respiratory sequelae

    Time frame: Baseline, week 2, Month 12, completion or failure of treatment (up to 12 months), Month 24

    Pulse oximetry

  16. Functional impact and repercussions of respiratory sequelae

    Time frame: Baseline, Month 2, completion or failure of treatment, Month 24

    Imaging (scanner)

  17. Functional impact and repercussions of respiratory sequelae

    Time frame: Baseline, Month 2, completion or failure of treatment (up to 12 months)

    Chest X-ray2.Other imaging for extrapulmonary involvement

  18. Quality of life and mental health

    Time frame: Baseline, During anti-tuberculosis treatment up to Month 12

    Psycho-trauma screening (PC-PTSD-5) - 20-item questionnaire, corresponding to the DSM-5 symptom criteria for PTSD. The self-report rating scale is 0-4 for each symptom, reflecting a change from 1-5 in the DSM-IV version.

  19. Quality of life and mental health

    Time frame: Baseline, Month 2, completion or failure of treatment (up to 12 months)

    Anxiety questionnaire (GAD-7) - Score 5-9: Mild Anxiety. Score 10-14: Moderate Anxiety. Score greater than 15: Severe Anxiety. EQ-5D-5L - The UI is calculated from patient scoring of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). For each dimension, participants are asked to mark between 1: 'no problems' to 5: 'unable to/extreme problems'. Depression (PHQ-9) -Total scores of 5, 10, 15 and 20 represent the thresholds for mild, moderate, moderately severe and severe depression, respectively. Note: Question 9 is a single screening question on suicide risk.

  20. Quality of life and mental health

    Time frame: Baseline, Day 3, Day 7

    Psycho-trauma screening (PC-PTSD-5) - 20-item questionnaire, corresponding to the DSM-5; .symptom criteria for PTSD. The self-report rating scale is 0-4 for each symptom, reflecting a change from 1-5 in the DSM-IV version.Hunger scale (HHS) - rating scale from 0 to 10, where 0 is painful hunger and 10 is painful fullness.

  21. Quality of life and mental health

    Time frame: Completion of treatment (up to 12 months)

    Stigma scale - Responses to each item are measured on a five-point scale (ranging from zero 'strongly disagree' to four 'strongly agree'). Higher scores indicate higher levels of depression stigma.

  22. Quality of life and mental health

    Time frame: Baseline to Month 24

    Alcohol questionnaire (AUDIT-C) - scored on a scale of 0-12 (scores of 0 reflect no alcohol use). In men, a score of 4 or more is considered positive; in women, a score of 3 or more is considered positive. Generally, the higher the AUDIT-C score, the more likely it is that the patient's drinking is affecting his/her health and safety. Tobacco questionnaire (Fagerström) - Test for Nicotine Dependence, the three yes/no items are scored 0 (no) and 1 (yes). The three multiple-choice items are scored from 0 to 3. The items are summed to yield a total score of 0-10.

  23. Adherence to tuberculosis treatment

    Time frame: Week 2, Month 2, completion of treatment

    Psychoactive substances questionnaire (CAGE-AID) - Item responses on the CAGE are scored 0 or 1, with a higher score an indication of alcohol problems. A total score of 2 or greater is considered clinically significant. A score of 2 to 3 indicates a high index of suspicion and a score of 4 is virtually diagnostic for alcoholism.

  24. Health literacy

    Time frame: Baseline, Day 3, Day 7

    Questionnaire

  25. Screening for precariousness

    Time frame: Baseline, Day 3, Day 7, Month 2, Month 12

    PRECAR score

  26. Complementary support for medical follow-up to compliance with treatment

    Time frame: Month 2, completion of treatment, Month 12

    Questionnaire

  27. Only in case of TB meningitis

    Time frame: Baseline, Month 2, completion or failure of treatment (up to 12 months)

    Neurocognitive scores - Rankin (MR,) - Measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.

    is a 6 point disability scale with possible scores ranging from 0 to 5. A separate category of 6 is usually added for patients who expire.

Study contacts

Contact information is provided by the study sponsor or research team.

Olivier MARCY, MD PHD

CONTACT

[email protected]

+33 5 57 57 17 67

Sponsors and collaborators

Lead sponsor

ANRS, Emerging Infectious Diseases

Other Gov

Collaborators

  • Amiens University Hospital
  • Centre Hospitalier Universitaire, Amiens
  • Centre National de la Recherche Scientifique, France
  • Claude Bernard University
  • Hôpital Jean Verdier
  • Institut National de la Santé Et de la Recherche Médicale, France
  • Saint Antoine University Hospital
  • Saint-Louis Hospital, Paris, France
  • University Hospital, Bordeaux
  • University of Bordeaux
  • University of Lyon

Registry information

Official study title

Prospective Cohort of People Starting Treatment for Tuberculosis Disease in France - ANRS 464s FrenchTB

Acronym: FrenchTB

Important dates

Study start
2026
Primary completion
2027
Study completion
2031
First posted
Mar 25, 2025
Registry last updated
Jun 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.